FILANA THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $26.6M | $69.6M | $89.4M | $68.0M | $24.8M |
| Operating expenses | $95.4M | $141.4M | $106.0M | $80.0M | $32.9M |
| Operating income | -$95.4M | -$141.4M | -$106.0M | -$80.0M | -$32.9M |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$91.0M | -$24.3M | -$97.2M | -$76.2M | -$32.4M |
| Balance Sheet | |||||
| Cash and equivalents | $95.5M | $128.6M | $121.1M | $201.0M | $233.4M |
| Current assets | $97.7M | $136.5M | $129.6M | $211.2M | $244.5M |
| Total assets | $118.4M | $157.5M | $151.7M | $234.8M | $266.8M |
| Current liabilities | $43.8M | $11.8M | $14.2M | $7.1M | $12.5M |
| Total liabilities | $44.0M | $11.8M | $14.2M | $7.3M | $12.9M |
| Stockholders' equity | $74.4M | $145.7M | $137.5M | $227.5M | $253.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$32.3M | -$116.9M | -$82.0M | -$77.5M | -$30.2M |
| Depreciation and amortization | $903,000 | $952,000 | $1.1M | $804,000 | $310,000 |
| Stock-based compensation | $19.6M | $16.3M | $4.6M | $2.1M | $1.8M |
| Capital expenditure | $581,000 | $103,000 | $414,000 | $2.7M | $22.2M |
| Free cash flow | -$32.8M | -$117.0M | -$82.4M | -$80.2M | -$52.4M |
Shares outstanding 48.3M · Free float 87.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.